Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Somatostatin receptor gene therapy combined with targeted therapy with radiolabeled octreotide: a new treatment for liver metastases.

Mearadji A, Breeman W, Hofland L, van Koetsveld P, Marquet R, Jeekel J, Krenning E, van Eijck C.

Ann Surg. 2002 Dec;236(6):722-8; discussion 728-9.

2.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
3.

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, De Jong M.

Q J Nucl Med Mol Imaging. 2007 Dec;51(4):324-33.

4.

Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.

De Jong M, Breeman WA, Bernard HF, Kooij PP, Slooter GD, Van Eijck CH, Kwekkeboom DJ, Valkema R, Mäcke HR, Krenning EP.

Q J Nucl Med. 1999 Dec;43(4):356-66.

PMID:
10731786
5.

Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.

Breeman WA, Mearadji A, Capello A, Bernard BF, van Eijck CH, Krenning EP, de Jong M.

Int J Cancer. 2003 Apr 10;104(3):376-9.

6.

Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.

De Jong M, Bernard BF, De Bruin E, Van Gameren A, Bakker WH, Visser TJ, Mäcke HR, Krenning EP.

Nucl Med Commun. 1998 Mar;19(3):283-8.

PMID:
9625504
8.

Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.

Swärd C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M, Forssell-Aronsson E, Nilsson O, Kölby L.

Cancer Biother Radiopharm. 2008 Feb;23(1):114-20. doi: 10.1089/cbr.2007.0421.

PMID:
18298335
9.

Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver.

Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH.

Int J Cancer. 1999 May 31;81(5):767-71.

10.

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP.

Int J Cancer. 2001 Jun 1;92(5):628-33.

11.

213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.

Norenberg JP, Krenning BJ, Konings IR, Kusewitt DF, Nayak TK, Anderson TL, de Jong M, Garmestani K, Brechbiel MW, Kvols LK.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):897-903.

12.

Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Maecke HR, Forssell-Aronsson E.

J Nucl Med. 2004 Sep;45(9):1542-8.

13.

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP.

J Clin Oncol. 2005 Apr 20;23(12):2754-62.

PMID:
15837990
14.

Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery.

Hofland LJ, Breeman WA, Krenning EP, de Jong M, Waaijers M, van Koetsveld PM, Mäcke HR, Lamberts SW.

Proc Assoc Am Physicians. 1999 Jan-Feb;111(1):63-9.

PMID:
9893158
15.

Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.

Capello A, Krenning EP, Breeman WA, Bernard BF, Konijnenberg MW, de Jong M.

Cancer Biother Radiopharm. 2003 Oct;18(5):761-8.

PMID:
14629824
16.

Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide.

van Eijck CH, Slooter GD, Hofland LJ, Kort W, Jeekel J, Lamberts SW, Marquet RL.

Br J Surg. 1994 Sep;81(9):1333-7.

PMID:
7953404
17.

Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.

De Jong M, Bakker WH, Breeman WA, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt M, Béhé M, Mäcke HR, Krenning EP.

Int J Cancer. 1998 Jan 30;75(3):406-11.

18.

Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.

van Vliet EI, Teunissen JJ, Kam BL, de Jong M, Krenning EP, Kwekkeboom DJ.

Neuroendocrinology. 2013;97(1):74-85. doi: 10.1159/000335018. Epub 2012 Jan 10. Review.

PMID:
22237390
19.

Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.

Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP.

Q J Nucl Med Mol Imaging. 2006 Dec;50(4):265-71. Review.

20.

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Teunissen JJ, Kwekkeboom DJ, Krenning EP.

J Clin Oncol. 2004 Jul 1;22(13):2724-9.

PMID:
15226340

Supplemental Content

Support Center